Companies
Multi-plant target accounts across all verticals.
ANI Pharmaceuticals
ANI Pharmaceuticals is undergoing a strategic shift toward rare disease specialization, with Cortrophin Gel emerging as a defining growth driver for 2026 and beyond. The company is expanding Cortrophin's market reach into acute gout treatment with a dedicated 90-person sales force while maintaining its core generic and specialty pharmaceutical manufacturing operations.
AbbVie
AbbVie is pursuing a ~$11B acquisition of Apogee Therapeutics to expand its inflammatory disease portfolio, particularly in atopic dermatitis, while maintaining strong momentum in immunology with Skyrizi and Rinvoq offsetting Humira declines. The company continues delivering FDA approvals and positive trial results, positioning it as a growth-driven dividend payer.
Abbott Laboratories
Abbott Laboratories, a diversified healthcare giant with 30+ US manufacturing locations, recently received FDA clearance for its next-generation Ultreon 3.0 AI-powered coronary imaging platform, demonstrating continued innovation in medical devices. The company maintains strong investor interest as a Dividend King with 54 consecutive years of dividend increases and a yield approaching 3%, though recent portfolio moves show some institutional reallocation away from the stock.
Agenus
Agenus is advancing its lead immunotherapy combination BOT/BAL through Phase III trials (BATTMAN) for metastatic colorectal cancer while generating early access revenues and strengthening its balance sheet. The company is leveraging AI-based tumor analysis and strategic partnerships to optimize clinical outcomes and pursue regulatory pathways in the US and Europe.
Agilent Technologies
Agilent Technologies maintains a strong position as a diversified life sciences and diagnostics instrumentation provider with established manufacturing across multiple U.S. locations. No recent operational or expansion activity is evident from available news sources.
Alcami
Alcami is a well-established CDMO with a diversified footprint across 770,000 sq ft of facilities in multiple regions, offering comprehensive services from analytical development through commercial manufacturing and storage. The company maintains a stable operational presence with no recent expansion announcements or significant market activity.
Alcon
Alcon is experiencing strong momentum in Q1 2026 with 10% revenue growth driven by new product launches including the UNITY® Cataract System and Tryptyr for dry eye disease. The company's Surgical and Vision Care segments both returned to 6% growth, demonstrating recovery despite ongoing competitive and macroeconomic pressures.
Align Technology
Align Technology is executing a leadership transition with a new Chairman appointment effective July 2026 while positioning itself as a comprehensive AI-powered digital dentistry platform beyond its flagship Invisalign product. The company is navigating mixed demand dynamics with North America pressure offset by strong international growth and dental service organization expansion.
Alkermes
Alkermes is advancing its orexin agonist program (alixorexton) into Phase 3 development with positive Phase 2 data and orphan drug designations, while integrating the Avadel Pharmaceuticals acquisition to strengthen its sleep disorder portfolio. The company is executing on a growth thesis centered on hypersomnolence and narcolepsy treatments alongside its core psychiatric medication business.
Alphatec Holdings
Alphatec Holdings is facing significant legal scrutiny with multiple class-action fraud investigations launched by major law firms regarding allegedly false or misleading statements. The company's core operations in spinal surgery technology remain intact, but investor confidence appears severely compromised.
Amgen
Amgen is actively competing in the high-growth obesity drug market alongside major competitors and facing significant patent challenges, with a Delaware jury finding willful infringement of Harbour BioMed's antibody patents. The company is also managing regulatory headwinds with an independent reassessment of Tavneos data following FDA withdrawal proposals.
Amneal Pharmaceuticals
Amneal is experiencing strong momentum with a 52-week high in stock price, driven by growth in generics, injectables, and a newly expanded biosimilars platform. The company is also expanding its market reach through strategic partnerships like the 'Hope Alliance' campaign to serve underserved patients.
AngioDynamics
AngioDynamics is rapidly advancing its NanoKnife IRE platform with FDA IDE approval for BPH treatment and recent Medicare coverage expansion for prostate and liver cancer applications. The company is generating strong analyst sentiment with 50-64% upside potential driven by NanoKnife adoption momentum and positive clinical trial data.
Arthrex
Arthrex is a leading privately-held medical device manufacturer specializing in minimally invasive orthopedic and sports medicine solutions with a robust multi-state manufacturing footprint. The company maintains significant operational scale with 7,000 employees and produces over 1,000 new products annually across five strategic facilities.
Artivion
Artivion completed its acquisition of Endospan Ltd. following FDA PMA approval of the NEXUS® Aortic Arch System in April 2026, strengthening its aortic disease portfolio. The company delivered 18% GAAP revenue growth in Q1 2026 to $116.3M, though it lowered full-year guidance due to softer stent graft trends.
Assertio Holdings
Assertio Holdings completed its merger with Zydus Lifesciences in May 2026, marking a significant corporate restructuring for the specialized pharma company. The transaction has drawn multiple shareholder lawsuits questioning deal fairness and process adequacy.
Atrion Corporation
Atrion Corporation is a diversified medical device manufacturer specializing in fluid management, cardiovascular, and ophthalmology products with established operations in Allen, TX. The recent news provided appears to reference Ares Management (ARES) rather than Atrion, making current operational activity unclear.
Avanos Medical
Avanos Medical is facing multiple shareholder lawsuits and M&A class action investigations regarding potentially unfair merger deals, signaling potential corporate restructuring activity. Recent financial performance shows mixed results with revenue beats offset by margin pressure and earnings misses.
Avantor
Avantor reported Q1 2026 results with revenue beats but margin compression and negative organic growth, signaling early stabilization rather than confirmed recovery. The company is executing strategic leadership changes and product portfolio expansions (Masterflex) while facing persistent challenges in its VWR Distribution & Services segment.
B. Braun Medical
B. Braun Medical operates a substantial U.S. manufacturing footprint with 9 known facilities across multiple states, leveraging its German parent company's resources to serve hospitals and healthcare providers. The company maintains diverse product lines spanning IV therapy, dialysis, anesthesia, and surgical instruments with no recent expansion activity reported.
Bausch + Lomb
Bausch + Lomb is a diversified global eye health leader with strong operational footprint across three segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The company maintains manufacturing capabilities in Rochester, NY and Greenville, SC while conducting R&D in Irvine, CA.
Bausch Health Companies
Bausch Health is executing a product innovation strategy across its divisions, with recent launches including PreserVision AREDS3 eye vitamins and Bi-Blade+ vitrectomy equipment, while also securing trademark recognition for its Solta Medical aesthetic business in China. The company faces operational headwinds with weak organic growth and stagnant volumes despite margin improvements, with investor focus on debt reduction as a key value driver.
Baxter International
Baxter beat Q1 2026 earnings and revenue estimates despite margin contraction and lower year-over-year profits, driven by strong demand in medical devices and therapies. The company is focused on business stabilization and operational improvement across its diversified manufacturing footprint.
Becton Dickinson
BD is leveraging AI-powered medication management systems and launching breakthrough vascular access technology (CentroVena One™) to strengthen its market position in medical devices. The company maintains a robust North American manufacturing footprint with 20+ plants while facing near-term earnings pressure from China dynamics and research funding headwinds.
Bio-Rad Laboratories
Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics with four major U.S. manufacturing facilities, maintains a strong market presence serving pharmaceutical, biotech, and clinical laboratory customers. The company's recent activity centers on industry participation at BIO International Convention 2026, though no direct company announcements were identified in this news cycle.
Bio-Techne
Bio-Techne is a diversified life sciences company with strong market positioning across protein sciences and diagnostics through recognized brands like R&D Systems and ProteinSimple. The company operates manufacturing facilities in Minneapolis and San Jose, serving global research and clinical diagnostic markets.
BioMarin Pharmaceutical
BioMarin achieved a major clinical milestone with VOXZOGO meeting its primary endpoint in a Phase 3 hypochondroplasia study, with plans for FDA filings in 2026, while experiencing mixed results from BMN 401 in an ENPP1 deficiency trial. The company continues advancing its rare disease therapeutic pipeline across multiple development programs.
Biogen
Biogen is expanding its immunology pipeline through the acquisition of RayThera for up to $1 billion, marking a strategic shift to diversify beyond its core neurology and Alzheimer's focus. The company is currently facing multiple shareholder fraud investigations related to potential misleading statements or disclosure failures.
Bioventus
Bioventus is a well-established medical technology company with a diversified orthopedic product portfolio spanning pain management, surgical innovations, and restorative therapies. The company operates from its Durham, NC headquarters with manufacturing capabilities in Duarte, CA, serving a broad base of orthopedic specialists across clinical settings.
Boehringer Ingelheim
Boehringer Ingelheim is a major global pharmaceutical manufacturer with significant US operations across multiple therapeutic areas including cardiovascular, respiratory, oncology, and metabolic treatments. The company maintains a diversified manufacturing footprint across nine known facilities in the US, supporting both pharmaceutical production and contract biopharmaceutical services.
Boston Scientific
Boston Scientific is experiencing significant market headwinds with a 50%+ year-to-date stock decline driven by guidance cuts, product deceleration (WATCHMAN), and clinical trial setbacks (CHAMPION-AF). Despite trading at a significant discount to peers (12.6x FY27E P/E), the company maintains operational stability with 53,000 employees across six manufacturing facilities.
Bristol-Myers Squibb
Bristol-Myers Squibb continues to strengthen its portfolio with FDA review of Camzyos for adolescent obstructive HCM, expanding cardiovascular market reach. The company maintains investor attention as a high-yield dividend stock positioned to weather rising interest rates in 2026.
Bruker Corporation
Bruker is experiencing strong momentum with 50.3% YoY stock growth, driven by BSI NANO expansion, AI-driven semiconductor metrology demand, and growing international orders offsetting U.S. academic funding weakness. The company is launching advanced platforms like timsMRMS for energy sector applications while expanding its microbiology and infection diagnostics portfolio.
CONMED Corporation
CONMED Corporation is an established medical technology company with a diverse portfolio spanning orthopedic surgical instruments, general surgical equipment, and endoscopic solutions, operating from three manufacturing facilities across Florida, New York, and Connecticut. The company maintains a stable operational footprint with 3,900 employees and serves hospitals and surgical centers through direct and distributor channels.
Cambrex
Cambrex is a well-established CDMO with a geographically diversified manufacturing and R&D footprint across 7 facilities in the US, serving clinical and commercial scale pharma/biotech clients. No recent expansion or operational news is available to assess current momentum.
Cardinal Health
Cardinal Health raised its 2026 profit forecast for the second time this year, driven by strong demand for specialty drugs and pharma growth despite a revenue miss in Q3. The company beat EPS estimates significantly ($3.17 vs $2.8 consensus) and increased its quarterly dividend, signaling confidence in operational performance.
Catalent
Catalent is a major CDMO with extensive U.S. manufacturing footprint across 21 facilities, recently acquired by Novo Holdings in December 2024. The company serves pharma, biologics, and gene therapy markets with integrated development and manufacturing capabilities.
Charles River Laboratories
Charles River Laboratories is strengthening its competitive position through strategic partnerships, notably joining Eli Lilly's TuneLab AI/ML drug discovery platform to leverage its nonclinical testing expertise. The company continues to maintain strong market visibility through investor conferences and analyst coverage, positioning itself as a key enabler of pharmaceutical innovation.
Coherus BioSciences
Coherus Oncology is advancing its oncology pipeline with key clinical readouts expected mid-2026, including data for casdozokitug in HCC and the JUPITER-02 trial for toripalimab in nasopharyngeal carcinoma. The company reported Q1 2026 LOQTORZI revenue of $11.8M and has completed patient accrual for its anti-IL27 Phase 2 trial, though it faces near-term liquidity concerns requiring potential financing.
DJO Global (Enovis)
Enovis (formerly DJO Global) is a diversified medical technology company with a strong portfolio in orthopedic devices, joint reconstructive implants, and pain management solutions. The company operates manufacturing facilities in California and Texas while maintaining its headquarters in Delaware.
DPT Laboratories
DPT Laboratories is an established CDMO with a 85+ year track record specializing in semi-solid and liquid dosage forms across non-sterile and sterile applications. Operating as a Viatris subsidiary with 1,000 employees across two Texas facilities and one New Jersey manufacturing site, the company maintains a stable operational footprint.
Danaher
Danaher completed its $9.9B acquisition of Masimo Corporation, significantly expanding its Diagnostics segment with AI-enabled patient-monitoring and sensor technologies. The company is experiencing strong biotech growth with equipment orders up over 30% and core revenue gains expected in 2026.
Dentsply Sirona
Dentsply Sirona is executing a 'Return-to-Growth' strategy while expanding its U.S. distribution network through partnerships like Nashville Dental, Inc to strengthen digital dentistry access. Recent Q1 2026 earnings missed estimates with margin pressure, though the company is investing in AI-enabled launches and distributor wins.
Dexcom
Dexcom is a leading continuous glucose monitoring (CGM) company with dual manufacturing footprint in San Diego and Germantown, MD, serving diabetes management across the US and internationally. The company maintains a robust product portfolio including the established G6 system and developing G7 next-generation platform, while advancing blood glucose monitoring innovations through a strategic partnership with Verily Life Sciences.
Edwards Lifesciences
Edwards Lifesciences is experiencing strong market momentum with regulatory tailwinds as CMS removes coverage restrictions on TAVR procedures, while the company demonstrates solid operational performance despite valuation debates. Recent leadership changes include a new CFO appointment, signaling ongoing organizational refinement.
Elanco Animal Health
Elanco is aggressively expanding its innovation portfolio with a new $25M venture capital platform and launching breakthrough products like Befrena™ (anti-IL-31 monoclonal antibody) and TruCan™ Ultra Lyme-L4 vaccine, positioning itself as a leader in companion animal therapeutics. The company is also capitalizing on emerging livestock health threats like New World screwworm, demonstrating market responsiveness and operational readiness.
Eli Lilly
Eli Lilly is aggressively expanding US manufacturing capacity with $21B+ invested in Indiana since 2020, including a new dedicated genetic medicine facility in Lebanon. The company's blockbuster weight-loss drugs (Mounjaro, Zepbound) and tirzepatide pipeline are driving strong financial performance and bullish analyst sentiment.
Emergent BioSolutions
Emergent BioSolutions is securing significant government contracts and expanding international regulatory approvals for key biodefense products, while diversifying revenue through CDMO partnerships. The company is actively leveraging its manufacturing infrastructure across multiple sites to support both internal pipeline development and third-party manufacturing agreements.
Envista Holdings
Envista is experiencing strong financial momentum with a 37.1% year-over-year stock rally driven by new product launches, margin expansion, and strategic acquisitions. The company is pursuing international expansion while maintaining operational excellence across its two-division dental solutions business.
Exact Sciences
Exact Sciences was recently acquired by Abbott Labs for approximately $23 billion, which is creating near-term earnings dilution for Abbott despite the strategic value of the cancer diagnostics portfolio. Institutional investors are showing mixed sentiment with some funds increasing positions while others are reducing stakes significantly.
Fresenius Kabi USA
Fresenius Kabi USA operates a significant US manufacturing footprint with 5 facilities across multiple states producing generic injectables, IV solutions, and nutrition products for critical care markets. The company maintains stable operations with no recent expansion or market activity reported.
GE HealthCare Technologies
GE HealthCare Technologies is a diversified medical technology leader with 53,000 employees operating four major business divisions (Imaging, Ultrasound, Patient Care Solutions, Pharmaceutical Diagnostics) across multiple manufacturing and R&D facilities in the US. The company maintains a strong global presence serving markets across North America, Europe, Asia, and Africa with integrated diagnostic and treatment solutions.
Gilead Sciences
Gilead Sciences is advancing its HIV treatment pipeline with FDA acceptance of Yeztugo as a once-weekly oral PrEP formulation, while maintaining its position as a global biopharmaceutical leader across HIV, hepatitis, and oncology markets. The company continues its humanitarian commitment with rapid donations of remdesivir for outbreak response and significant community investments in HIV/AIDS education.
Globus Medical
Globus Medical is capitalizing on strong musculoskeletal market growth with double-digit spine revenue gains, trauma demand increases, and strategic shifts toward recurring revenue models through robotics leasing. The company maintains financial strength with a debt-free balance sheet and ~$630M in liquid assets, supporting aggressive R&D and product launch acceleration.
Grifols USA
Grifols USA is a major plasma-derived therapeutics and diagnostics manufacturer generating over $3 billion in annual revenue across five key US facilities. The company maintains substantial operations in manufacturing, R&D, and shared services with 13,000 employees.
Guardant Health
Guardant Health is experiencing significant momentum in its precision oncology platform, with recent FDA approvals of Guardant360 CDx as a companion diagnostic and major clinical validation through American Cancer Society recommendations for its Shield blood test in colorectal cancer screening. The company is demonstrating broad market traction with 38 research abstracts being presented at ASCO 2026, indicating expanding clinical utility and partnership strength.
Haemonetics
Haemonetics is actively positioning itself in the medical technology market, recently updating its financial reporting segments to better align with internal business management. The company's CEO is presenting at major industry conferences, indicating strategic investor engagement and market confidence.
Herbalife
Herbalife Nutrition operates as a global nutrition enterprise with dual manufacturing presence in Los Angeles and Charlotte, leveraging a multi-channel distribution model through independent representatives and retail platforms. The company maintains a broad product portfolio spanning weight management, supplements, sports nutrition, and personal care across major international markets.
Hologic
Hologic completed its acquisition by Blackstone and TPG, transitioning to private ownership with new CEO Joe Almeida following founder Steve MacMillan's retirement. The company continues advancing its core women's health diagnostics and imaging portfolio, recently securing patent victories against competitors and expanding regulatory approvals for its Aptima HPV assay.
ICU Medical
ICU Medical beat Q1 2026 earnings expectations with $1.97 EPS versus consensus of $1.78, demonstrating strong operational performance in infusion therapy and critical care devices. The company is navigating the integration of The Smiths Group acquisition while maintaining its market position as a leader in medical device manufacturing.
Illumina
Illumina is experiencing strong momentum with its NovaSeq X platform driving adoption and clinical sequencing demand, supported by a 98.7% stock surge over the past year. The company continues expanding its product portfolio with launches like StrataMap Spatial Solution and integrated oncology research workflows, solidifying its leadership in genomic analysis.
Inogen
Inogen is navigating mixed Q1 2026 results with revenue growth and margin improvements offset by U.S. market headwinds from channel shifts. The company is diversifying beyond portable oxygen concentrators into broader home respiratory care while experiencing strong international demand.
Insulet Corporation
Insulet is experiencing strong momentum with Q1 2026 revenue growth of 33.9% YoY and management forecasting 21-23% growth for 2026, driven by Omnipod 5 adoption and international expansion. The company is advancing its product pipeline with new data on Omnipod 6 and fully closed-loop AID systems while expanding sensor compatibility with Abbott's FreeStyle Libre 3 Plus.
Integer Holdings
Integer Holdings, a leading medical device CDMO, is undergoing a strategic review with potential acquisition interest, trading at a depressed valuation despite strong operational fundamentals and diverse product portfolio across cardiac, neuromodulation, and surgical markets. The company is managing through a temporary growth slowdown with customer forecast changes and slower product ramps, while maintaining revenue growth and beating estimates on key product lines.
Integra LifeSciences
Integra LifeSciences is experiencing strong stock momentum, hitting 52-week highs with 15% gains since the last earnings report, positioning itself as an attractive value and GARP stock option. The company continues to leverage its dual business segments (Codman Specialty Surgical and Tissue Technologies) across global markets while maintaining leadership in surgical implants and regenerative medicine.
Intuitive Surgical
Intuitive Surgical is a dominant medical technology leader with flagship da Vinci Surgical System and growing Ion endoluminal portfolio serving minimally invasive procedures globally. The company maintains dual manufacturing presence in California with established operations and comprehensive service ecosystem across 15,638 employees.
Invacare
Invacare is a established medical device manufacturer with a diversified portfolio across mobility, respiratory therapy, and daily living aids, operating three manufacturing facilities across the US. The company serves home healthcare, retail, and institutional care markets through a broad distribution network.
Ionis Pharmaceuticals
Ionis is transitioning from a niche RNA-therapeutics company to a commercial-stage biopharmaceutical powerhouse with multiple Phase 3 candidates approaching regulatory milestones and projected 2030 revenues exceeding $5 billion. Recent partner wins, including GSK's breakthrough bepirovirsen hepatitis B data and board leadership additions, underscore strong momentum in expanding its therapeutic reach beyond rare diseases into multi-billion-dollar markets.
Jamieson Wellness
Jamieson Wellness is a Canadian-listed nutraceuticals company with significant operations in China through its Jowell Global subsidiary, which operates an extensive e-commerce platform and 26,000+ physical retail stores. Recent activity includes credit facility refinancing extended to 2031 and Q1 2026 earnings announcements, indicating stable financial management and ongoing operations.
Jazz Pharmaceuticals
Jazz Pharmaceuticals signed a major $876M collaboration with AbCellera to develop next-generation T-cell engaging antibodies for solid tumors, marking significant oncology pipeline expansion. However, the company faced a setback with Zepzelca failing to meet primary survival endpoints in a Phase 3 lung cancer trial.
Johnson & Johnson
Johnson & Johnson maintains a streamlined portfolio focused on Innovative Medicine and MedTech following its 2023 divestiture of Consumer Health to Kenvue, positioning itself for higher-growth innovation. Recent market commentary highlights J&J as a defensive dividend stock attracting capital away from the technology sector amid market volatility concerns.
KBI Biopharma
KBI Biopharma is a well-established CDMO with significant manufacturing footprint across five major facilities spanning mammalian, microbial, and cell therapy capabilities. The company maintains a stable operational base with 1,650 employees serving pharma and biotech clients across development and commercial stages.
Lannett Company
Lannett Company is undergoing acquisition by Aurobindo Pharma for $250 million, pending FTC approval requiring divestiture of four drug products. The company recently achieved FDA approval for LANGLARA™, an interchangeable biosimilar insulin glargine, marking expansion into the biosimilar market.
Lantheus Holdings
Lantheus is experiencing strong momentum with its turnaround strategy gaining traction, evidenced by stock hitting 52-week highs and exceeded earnings expectations. The company's pipeline, particularly PYLARIFY for prostate cancer imaging, is shifting market perception and driving valuation reassessment.
LifeNet Health
LifeNet Health completed landmark drone transportation trials of human kidneys in partnership with NASA and UNOS, demonstrating critical logistics innovation for organ delivery. The company is simultaneously scaling its regenerative medicine platform globally through digital infrastructure upgrades and partnerships with biotech firms like Inotiv.
Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals is a specialty pharma company with significant manufacturing footprint across 8 US facilities focused on rare diseases and critical care therapies. The company recently underwent structural changes following its 2025 merger with Endo, with legacy operations continuing under the Keenova Therapeutics umbrella.
Masimo
Masimo is undergoing a transformative acquisition by Danaher Corporation, with shareholders approving the merger agreement in February 2026. The company continues to validate its flagship SET pulse oximetry technology across diverse patient populations, recently demonstrating accuracy across all skin tones in newborns, while facing ongoing IP disputes with Apple.
Medtronic
Medtronic completed its $550 million acquisition of Scientia Vascular to expand its neurovascular care portfolio, while the company is strategically focused on growth drivers in ablation, robotics, and hypertension therapies. The stock is trading at a discount valuation with a 3.5% dividend yield and 49 consecutive years of dividend increases, signaling stability amid near-term headwinds from tariffs and pricing pressures.
Merck & Co.
Merck is expanding its vaccine portfolio with FDA approval for Capvaxive's use in at-risk children and adolescents, while strengthening its drug discovery pipeline through a new AI collaboration with Protillion Biosciences. The company is also advancing its oncology leadership with FDA approvals for Keytruda combinations in renal cell carcinoma treatment.
Meridian Bioscience
VivoPower PLC is actively pivoting toward AI data center infrastructure and renewable energy, having acquired a 41.5MW facility in Norway and secured ex-SpaceX battery engineering talent to strengthen its power systems expertise. The company has shortlisted multiple AI operator tenants for its Norwegian data center and recently achieved B Corp recertification with an improved impact score, signaling strong commitment to sustainable infrastructure.
Merit Medical Systems
Merit Medical Systems is a diversified medical device manufacturer with strong therapeutic positioning in cardiology, oncology, and endoscopy, though facing headwinds from tariffs, OEM weakness, and China market pressures in 2026. The company maintains a geographically distributed manufacturing footprint across five U.S. facilities while actively engaging investor relations at major healthcare conferences.
MiMedx Group
MiMedx Group recently cut guidance, prompting mixed analyst responses though Craig-Hallum maintained a Buy rating. The company's leadership underwent shareholder-approved board and compensation changes, signaling governance adjustments amid market pressures.
Myriad Genetics
Myriad Genetics is aggressively expanding its oncology portfolio with AI-integrated diagnostics, launching Prolaris + AI and showcasing broad clinical utility of its Precise MRD assay at major medical conferences. The company appointed a new CTO in June 2026 to accelerate technology innovation and scaling, while trading at a depressed valuation that analysts view as a potential buying opportunity.
Natural Alternatives International (NAIA)
Natural Alternatives International is a pharmaceutical company headquartered and manufacturing in Chatsworth, CA with a focused operational footprint. No recent news or activity is available to assess current operational status or market developments.
Nature's Sunshine Products
Nature's Sunshine Products is an established nutraceutical manufacturer with a 52-year operational history, maintaining a global distribution network across multiple continents through independent sales consultants. The company operates dual manufacturing facilities in Utah with a lean workforce of 819 employees.
Neogen Corporation
Neogen reported Q3 2026 earnings that beat estimates with $0.09 EPS versus $0.04 consensus, though gross margins declined and stock fell nearly 3% post-results. The company is advancing its strategic transformation while managing headwinds in its animal safety division, including third-party business challenges.
Omeros Corporation
Omeros has transitioned to commercial stage with FDA approval and Q1 2026 launch of YARTEMLEA for TA-TMA, generating $11.1M in gross product sales. The company has secured a significant development deal with Novo Nordisk and is experiencing positive analyst sentiment with a 222.8% upside consensus price target.
OraSure Technologies
OraSure Technologies secured FDA clearance for its Colli-Pee Dx Urine Collection Kit for STI testing with Roche's diagnostic platforms, expanding its patient-friendly testing portfolio. The company reported Q1 2026 financial results and made board governance changes including a cooperation agreement with Altai Capital regarding board declassification.
Organogenesis Holdings
Organogenesis is a well-established regenerative medicine company with a diversified portfolio of advanced wound care and surgical/sports medicine products distributed across hospitals and surgical centers. The company maintains a stable operational footprint with manufacturing in Massachusetts and a pipeline of innovative products in development.
PCI Pharma Services
PCI Pharma Services is a well-established global CDMO with 8,000 employees operating 38 GMP facilities across seven countries, providing comprehensive pharmaceutical manufacturing services from clinical to commercial stages. The company is backed by major investors (Bain Capital, Kohlberg, Mubadala) and maintains a significant U.S. manufacturing footprint across six strategic locations.
Penumbra
Penumbra received FDA clearance and CE Mark for THUNDERBOLT, its innovative Computer Assisted Vacuum Thrombectomy (CAVT) technology for acute ischemic stroke, significantly expanding its global stroke care portfolio. However, the company missed Q1 2026 earnings estimates ($0.82 vs. $1.11 consensus) and experienced recent portfolio divestment from institutional investors.
Perrigo
Perrigo is navigating significant leadership transitions following CEO Patrick Lockwood-Taylor's resignation over personal conduct violations, with interim CEO Albert Manzone now steering the company. The company faces financial headwinds with an unsustainable dividend yield of 10.9%, distressed balance sheet, and recent asset divestitures including its Dermacosmetics business, though Q1 earnings beat estimates and specialty care brands show momentum.
PetIQ
PetIQ completed the sale of its veterinary services business (VIP Petcare) to Tractor Supply Company, marking a strategic pivot to focus on branded pet health and wellness products. The company maintains a dual-segment operation with significant product distribution across 60,000 points and manufacturing presence in Idaho and Nebraska.
Pfizer
Pfizer beat Q1 2026 earnings expectations with $14.5B in revenue, driven by strong performance from launched and acquired drugs, though adjusted EPS declined 18% year-over-year. The company faces a significant $17B patent cliff from key drug expirations like Eliquis and Vyndaqel, requiring successful pipeline launches and acquired product integration to sustain growth.
Phibro Animal Health
Phibro Animal Health is a diversified animal health and nutrition company with stable operations across three segments (Animal Health, Mineral Nutrition, Performance Products) serving global markets primarily through U.S. livestock channels. Recent market activity shows the stock trading at perceived undervaluation with insider buying interest, though analyst sentiment remains cautiously optimistic with limited near-term catalysts.
Quest Diagnostics
Quest Diagnostics is a leading diagnostic testing provider with strong market momentum and upgraded analyst ratings, benefiting from industry trends like aging populations and telehealth adoption. The company is actively engaged in research and sustainability initiatives while maintaining its core operations across five major manufacturing and laboratory facilities.
Quidel (QuidelOrtho)
QuidelOrtho is a diversified diagnostic testing company with established manufacturing footprints in San Diego and New Jersey, serving clinical and point-of-care markets globally. No recent operational or expansion activity is currently reported.
Regeneron Pharmaceuticals
Regeneron is experiencing strong stock performance (up 58% YTD) driven by EYLEA HD's 52% Q1 2026 sales surge and robust DUPIXENT growth across multiple indications. The company is actively expanding its pipeline through a $4 billion CytomX partnership for bispecific cancer therapeutics while facing ongoing investor litigation investigations.
ResMed
ResMed completed its $340 million acquisition of Noctrix Health to expand its clinical sleep health portfolio with wearable therapeutics for neurological disorders. The company faces mixed analyst sentiment with concerns about GLP-1 drug competition and market pressures, though management maintains confidence in long-term growth prospects.
Sandoz
Sandoz operates a diversified manufacturing footprint across the United States with facilities in New Jersey, Colorado, and California, alongside international operations. The company maintains a significant presence in generic pharmaceuticals and biosimilars production.
Starkey Hearing Technologies
Starkey Hearing Technologies remains the only American-owned global hearing aid manufacturer, leveraging a dual manufacturing footprint in Minnesota and Indiana. The company continues integrating AI and wireless connectivity into its product portfolio across three brands (Starkey, Audibel, NuEar).
Steris
STERIS reported record annual revenue for fiscal 2026 with solid gains across Healthcare and Applied Sterilization Technologies segments, though Q4 results slightly missed estimates. The company is guiding mid- to high-single-digit growth for fiscal 2027, betting on resilient procedure demand and continued pricing power despite FX volatility and macro headwinds.
Stryker
Stryker is actively launching innovative surgical products including the TPX HD power tool and Pangea Plating System while expanding globally, demonstrating strong procedure demand and market momentum. The company is also pursuing strategic acquisitions, notably the $835M acquisition of Amplitude Vascular Systems to strengthen its vascular and neurotechnology portfolio.
Tandem Diabetes Care
Tandem Diabetes Care is a established medical device company with a strong market position in insulin delivery systems, particularly through its t:slim X2 platform and integrated diabetes management solutions. The company maintains strategic partnerships with industry leaders like Dexcom and Abbott to enhance its product ecosystem.
Teleflex
Teleflex is executing a major portfolio reset with $2.03B in planned divestitures while managing margin compression and operating profit declines in Q1 2026. The company is advancing clinical programs (Freesolve resorbable scaffold, UroLift System) and securing $500M in debt financing to support financial restructuring.
The Cooper Companies
The Cooper Companies beat Q2 2026 earnings estimates with $1.21 EPS vs. $1.1 consensus, driven by strong CooperVision momentum in EMEA and Americas despite Asia Pacific softness. The company continues navigating litigation charges from embryo culture media recalls that have impacted profitability, while maintaining robust revenue growth across its two core business units.
Thermo Fisher Scientific
Thermo Fisher Scientific is advancing its analytical instruments portfolio with next-generation Orbitrap mass spectrometry platforms unveiled at ASMS 2026, while maintaining strong market position with a 6.8% stock surge and positive analyst sentiment. The company continues operational excellence across its six manufacturing facilities while returning capital to shareholders through quarterly dividends.
USANA Health Sciences
USANA Health Sciences operates a vertically integrated nutritional supplement and personal care business with manufacturing capabilities in Salt Lake City. The company maintains a direct-to-consumer distribution model across Asia Pacific, Americas, and Europe with established research partnerships.
Ultragenyx Pharmaceutical
Ultragenyx is actively hiring non-executive officers with multiple inducement grants issued in recent weeks, signaling organizational growth and expansion. The company faces shareholder litigation concerns regarding potential disclosure breaches, which has contributed to a 13.6% stock decline since last earnings.
Varex Imaging
Varex Imaging is trading at an undervalued price point with Wall Street analysts projecting 78% upside potential, supported by solid demand across both medical and industrial imaging segments. The company recently completed debt refinancing and continues investing in advanced imaging technologies while maintaining a global operational footprint.
Vertex Pharmaceuticals
Vertex Pharmaceuticals maintains its competitive position in the non-opioid pain management market with VX-548 in Phase 2 trials, while advancing CASGEVY® (exagamglogene autotemcel) for sickle cell disease and beta-thalassemia with recent pediatric data presentations and additional global regulatory submissions. The company's stock shows typical market volatility with mixed trading activity around the $435-$459 range.
Viatris
Viatris is leveraging biosimilars, complex generics, and specialty drugs as growth drivers while advancing its non-opioid pain therapy pipeline with FDA acceptance of fast-acting meloxicam (MR-107A-02). The company maintains a strong market position as a value stock with five operational manufacturing facilities supporting its global pharmaceutical portfolio.
West Pharmaceutical Services
West Pharmaceutical Services appointed Michel Lagarde as new CEO in June 2026, signaling leadership transition for growth initiatives. The company recovered from a recent cyberattack with no material impact to 2026 forecast, while positioned to benefit from GLP-1 drug demand and Annex 1 regulatory conversions.
Zimmer Biomet
Zimmer Biomet maintains a strong market position in musculoskeletal healthcare with solid financial performance (9.3% net sales growth, 15.5% adjusted EPS growth, 73.0% gross margin). The company is actively engaging with institutional investors at major healthcare conferences while maintaining shareholder returns through quarterly dividends.
Zoetis
Zoetis is facing significant legal challenges with multiple securities fraud class action lawsuits filed for alleged material misstatements regarding product adoption between January 2025 and May 2026. The company remains operationally focused on its core animal health business across four manufacturing facilities, but investor confidence appears shaken by litigation.
iRhythm Technologies
iRhythm Technologies is experiencing strong momentum with 25.7% revenue growth, improved profitability, and a favorable Medicare coverage update driving business expansion. The company is advancing AI-driven margin initiatives and maintaining strategic partnerships with Verily Life Sciences while managing a recent cybersecurity incident with no impact on device systems.